CLINICAL_TRIALS
trial_result
· 2014-01-20
Clinical Trial Update: Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma [Phase 2]
Summary
This is a completed Phase 2 trial of dasatinib in patients with recurrent or advanced-stage melanoma, with results posted in January 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2014-01-20